nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Ataxia—Vincristine—muscle cancer	0.0221	0.0247	CcSEcCtD
Methsuximide—Pancytopenia—Dactinomycin—muscle cancer	0.0216	0.0242	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.0201	0.0225	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.0196	0.187	CbGpPWpGaD
Methsuximide—Pancytopenia—Vincristine—muscle cancer	0.0193	0.0216	CcSEcCtD
Methsuximide—Weight decreased—Vincristine—muscle cancer	0.0184	0.0206	CcSEcCtD
Methsuximide—Proteinuria—Methotrexate—muscle cancer	0.0179	0.02	CcSEcCtD
Methsuximide—Protein urine present—Methotrexate—muscle cancer	0.0177	0.0197	CcSEcCtD
Methsuximide—Erythema multiforme—Dactinomycin—muscle cancer	0.0172	0.0193	CcSEcCtD
Methsuximide—Pancytopenia—Etoposide—muscle cancer	0.0157	0.0175	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.0146	0.0163	CcSEcCtD
Methsuximide—Leukopenia—Dactinomycin—muscle cancer	0.0142	0.0159	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—muscle cancer	0.0136	0.0152	CcSEcCtD
Methsuximide—Leukopenia—Vincristine—muscle cancer	0.0127	0.0142	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.0127	0.12	CbGpPWpGaD
Methsuximide—Erythema multiforme—Etoposide—muscle cancer	0.0125	0.0139	CcSEcCtD
Methsuximide—Anorexia—Dactinomycin—muscle cancer	0.0123	0.0138	CcSEcCtD
Methsuximide—Decreased appetite—Dactinomycin—muscle cancer	0.0113	0.0126	CcSEcCtD
Methsuximide—Anorexia—Vincristine—muscle cancer	0.011	0.0123	CcSEcCtD
Methsuximide—Irritability—Methotrexate—muscle cancer	0.0109	0.0122	CcSEcCtD
Methsuximide—Ataxia—Methotrexate—muscle cancer	0.0107	0.012	CcSEcCtD
Methsuximide—Feeling abnormal—Dactinomycin—muscle cancer	0.0107	0.0119	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.0106	0.0118	CcSEcCtD
Methsuximide—Insomnia—Vincristine—muscle cancer	0.0105	0.0117	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—muscle cancer	0.0103	0.0115	CcSEcCtD
Methsuximide—Abdominal pain—Dactinomycin—muscle cancer	0.0102	0.0114	CcSEcCtD
Methsuximide—Decreased appetite—Vincristine—muscle cancer	0.0101	0.0112	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00999	0.0112	CcSEcCtD
Methsuximide—Constipation—Vincristine—muscle cancer	0.0099	0.0111	CcSEcCtD
Methsuximide—Eosinophilia—Methotrexate—muscle cancer	0.00978	0.0109	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vincristine—muscle cancer	0.00946	0.0106	CcSEcCtD
Methsuximide—Confusional state—Etoposide—muscle cancer	0.00945	0.0106	CcSEcCtD
Methsuximide—Pancytopenia—Methotrexate—muscle cancer	0.00938	0.0105	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—muscle cancer	0.0093	0.0104	CcSEcCtD
Methsuximide—Abdominal pain—Vincristine—muscle cancer	0.00915	0.0102	CcSEcCtD
Methsuximide—Anorexia—Etoposide—muscle cancer	0.00894	0.00998	CcSEcCtD
Methsuximide—Diarrhoea—Dactinomycin—muscle cancer	0.00886	0.0099	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—muscle cancer	0.0088	0.00984	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00873	0.00975	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—muscle cancer	0.00847	0.00946	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—muscle cancer	0.00839	0.00938	CcSEcCtD
Methsuximide—Somnolence—Etoposide—muscle cancer	0.00833	0.00931	CcSEcCtD
Methsuximide—Vomiting—Dactinomycin—muscle cancer	0.00824	0.0092	CcSEcCtD
Methsuximide—Rash—Dactinomycin—muscle cancer	0.00817	0.00913	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—muscle cancer	0.00815	0.00911	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—muscle cancer	0.00812	0.00907	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—muscle cancer	0.00809	0.00904	CcSEcCtD
Methsuximide—Constipation—Etoposide—muscle cancer	0.00802	0.00896	CcSEcCtD
Methsuximide—Diarrhoea—Vincristine—muscle cancer	0.00792	0.00885	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—muscle cancer	0.00774	0.00864	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—muscle cancer	0.00772	0.00863	CcSEcCtD
Methsuximide—Nausea—Dactinomycin—muscle cancer	0.00769	0.0086	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—muscle cancer	0.00767	0.00857	CcSEcCtD
Methsuximide—Dizziness—Vincristine—muscle cancer	0.00765	0.00855	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—muscle cancer	0.00762	0.00852	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00756	0.00845	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—muscle cancer	0.00747	0.00835	CcSEcCtD
Methsuximide—Urticaria—Etoposide—muscle cancer	0.00745	0.00832	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—muscle cancer	0.00741	0.00828	CcSEcCtD
Methsuximide—Vomiting—Vincristine—muscle cancer	0.00736	0.00822	CcSEcCtD
Methsuximide—Rash—Vincristine—muscle cancer	0.0073	0.00815	CcSEcCtD
Methsuximide—Dermatitis—Vincristine—muscle cancer	0.00729	0.00815	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—muscle cancer	0.00727	0.00812	CcSEcCtD
Methsuximide—Headache—Vincristine—muscle cancer	0.00725	0.0081	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.00715	0.068	CbGpPWpGaD
Methsuximide—Nausea—Vincristine—muscle cancer	0.00687	0.00768	CcSEcCtD
Methsuximide—Vision blurred—Methotrexate—muscle cancer	0.00648	0.00725	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—muscle cancer	0.00647	0.00723	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—muscle cancer	0.00641	0.00717	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—MYF6—muscle cancer	0.00621	0.0591	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MYF5—muscle cancer	0.00621	0.0591	CbGpPWpGaD
Methsuximide—Dizziness—Etoposide—muscle cancer	0.0062	0.00693	CcSEcCtD
Methsuximide—Leukopenia—Methotrexate—muscle cancer	0.00616	0.00688	CcSEcCtD
Methsuximide—Vomiting—Etoposide—muscle cancer	0.00596	0.00666	CcSEcCtD
Methsuximide—Rash—Etoposide—muscle cancer	0.00591	0.0066	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—muscle cancer	0.00591	0.0066	CcSEcCtD
Methsuximide—Headache—Etoposide—muscle cancer	0.00587	0.00656	CcSEcCtD
Methsuximide—Tension—Doxorubicin—muscle cancer	0.00585	0.00653	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—muscle cancer	0.00579	0.00647	CcSEcCtD
Methsuximide—Confusional state—Methotrexate—muscle cancer	0.00566	0.00633	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—muscle cancer	0.00561	0.00627	CcSEcCtD
Methsuximide—Nausea—Etoposide—muscle cancer	0.00557	0.00622	CcSEcCtD
Methsuximide—Anorexia—Methotrexate—muscle cancer	0.00535	0.00598	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—muscle cancer	0.00533	0.00596	CcSEcCtD
Methsuximide—Insomnia—Methotrexate—muscle cancer	0.00508	0.00567	CcSEcCtD
Methsuximide—Somnolence—Methotrexate—muscle cancer	0.00499	0.00558	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—muscle cancer	0.0049	0.00548	CcSEcCtD
Methsuximide—Decreased appetite—Methotrexate—muscle cancer	0.00488	0.00545	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00485	0.00542	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—muscle cancer	0.00463	0.00518	CcSEcCtD
Methsuximide—Feeling abnormal—Methotrexate—muscle cancer	0.00463	0.00517	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—muscle cancer	0.00459	0.00513	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MYF6—muscle cancer	0.00458	0.0436	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MYF5—muscle cancer	0.00458	0.0436	CbGpPWpGaD
Methsuximide—Urticaria—Methotrexate—muscle cancer	0.00446	0.00498	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—muscle cancer	0.00444	0.00496	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MYF5—muscle cancer	0.00443	0.0422	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MYF6—muscle cancer	0.00443	0.0422	CbGpPWpGaD
Methsuximide—Insomnia—Doxorubicin—muscle cancer	0.0044	0.00491	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—muscle cancer	0.00432	0.00483	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—muscle cancer	0.00423	0.00472	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.0042	0.00469	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—muscle cancer	0.00416	0.00465	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—muscle cancer	0.00401	0.00448	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—MYOG—muscle cancer	0.004	0.0381	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00398	0.00444	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—muscle cancer	0.00386	0.00432	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—muscle cancer	0.00384	0.00429	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—muscle cancer	0.00384	0.00429	CcSEcCtD
Methsuximide—Dizziness—Methotrexate—muscle cancer	0.00371	0.00415	CcSEcCtD
Methsuximide—Vomiting—Methotrexate—muscle cancer	0.00357	0.00399	CcSEcCtD
Methsuximide—Rash—Methotrexate—muscle cancer	0.00354	0.00396	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—muscle cancer	0.00354	0.00395	CcSEcCtD
Methsuximide—Headache—Methotrexate—muscle cancer	0.00352	0.00393	CcSEcCtD
Methsuximide—Nausea—Methotrexate—muscle cancer	0.00334	0.00373	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—muscle cancer	0.00333	0.00372	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—muscle cancer	0.00322	0.00359	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—muscle cancer	0.00309	0.00345	CcSEcCtD
Methsuximide—Rash—Doxorubicin—muscle cancer	0.00307	0.00343	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—muscle cancer	0.00306	0.00342	CcSEcCtD
Methsuximide—Headache—Doxorubicin—muscle cancer	0.00305	0.0034	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MYOG—muscle cancer	0.00295	0.0281	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—muscle cancer	0.00289	0.00323	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MYOG—muscle cancer	0.00286	0.0272	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MYOD1—muscle cancer	0.00247	0.0235	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.00243	0.0231	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MED12—muscle cancer	0.00226	0.0215	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MYOD1—muscle cancer	0.00182	0.0173	CbGpPWpGaD
Methsuximide—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	0.00177	0.0169	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MYOD1—muscle cancer	0.00176	0.0168	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MED12—muscle cancer	0.00167	0.0159	CbGpPWpGaD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00164	0.0156	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MED12—muscle cancer	0.00161	0.0154	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—FOXO1—muscle cancer	0.00124	0.0118	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—FOXO1—muscle cancer	0.000915	0.0087	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—FOXO1—muscle cancer	0.000886	0.00843	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—muscle cancer	0.000792	0.00754	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000663	0.00631	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—muscle cancer	0.000584	0.00556	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—muscle cancer	0.000566	0.00538	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—muscle cancer	0.000565	0.00538	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—muscle cancer	0.000417	0.00397	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—muscle cancer	0.000404	0.00384	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000299	0.00284	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—FH—muscle cancer	0.000235	0.00224	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MED12—muscle cancer	0.000133	0.00127	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—muscle cancer	0.000121	0.00115	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.48e-05	0.000902	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—muscle cancer	4.22e-05	0.000402	CbGpPWpGaD
